[
  {
    "question": {
      "question_id": "cs03_q05_negative",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 15,
      "question_type": "negative",
      "prompt": "Is there evidence of nephrotoxicity or renal dysfunction in enrolled subjects?",
      "ground_truth": {
        "canonical_answer": "No. Renal panels (creatinine, BUN, eGFR) remain within normal limits throughout the trial. The emerging safety signal is hepatic, not renal.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_004",
          "clinical_signal_03_ep_011"
        ],
        "key_facts": [
          "the adverse signal is hepatic (ALT/AST elevation), not renal \u2014 kidney function markers remain stable while liver enzymes diverge",
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases"
        ]
      }
    },
    "answer": {
      "question_id": "cs03_q05_negative",
      "answer_text": "There is no evidence of nephrotoxicity or renal dysfunction in the enrolled subjects based on the available data. Searches across safety reports and lab results, specifically filtered for renal function and nephrotoxicity, returned no relevant findings [ref_id: clinical_signal_03_ep_013, ref_id: clinical_signal_03_ep_005, ref_id: clinical_signal_03_ep_011]. Additionally, no documents from the safety or lab results scopes mention adverse events or abnormalities related to kidney function [ref_id: clinical_signal_03_ep_004, ref_id: clinical_signal_03_ep_008].",
      "turns": [
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_63db0eba7d1249bda0a69bc8",
              "name": "memory_capabilities",
              "arguments": {}
            }
          ],
          "tokens_used": 749
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_72255efd22a94e359088c6ba",
              "name": "memory_search",
              "arguments": {
                "query": "nephrotoxicity renal dysfunction enrolled subjects",
                "limit": 7
              }
            }
          ],
          "tokens_used": 1052
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_a7ff10240a7f4d698305868b",
              "name": "memory_search",
              "arguments": {
                "query": "renal function nephrotoxicity adverse events",
                "limit": 7
              }
            }
          ],
          "tokens_used": 3167
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_74af678723704c8da3931166",
              "name": "memory_search",
              "arguments": {
                "query": "renal adverse events nephrotoxicity lab results",
                "limit": 7,
                "filters": {
                  "scope_id": "safety"
                }
              }
            }
          ],
          "tokens_used": 5296
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_134de86b0dd44f70a01eadc6",
              "name": "memory_search",
              "arguments": {
                "query": "renal function nephrotoxicity",
                "limit": 7,
                "filters": {
                  "scope_id": "lab_results"
                }
              }
            }
          ],
          "tokens_used": 5353
        },
        {
          "role": "assistant",
          "content": "There is no evidence of nephrotoxicity or renal dysfunction in the enrolled subjects based on the available data. Searches across safety reports and lab results, specifically filtered for renal function and nephrotoxicity, returned no relevant findings [ref_id: clinical_signal_03_ep_013, ref_id: clinical_signal_03_ep_005, ref_id: clinical_signal_03_ep_011]. Additionally, no documents from the safety or lab results scopes mention adverse events or abnormalities related to kidney function [ref_id: clinical_signal_03_ep_004, ref_id: clinical_signal_03_ep_008].",
          "tokens_used": 5506
        }
      ],
      "tool_calls_made": 5,
      "total_tokens": 21123,
      "wall_time_ms": 12304.14216290228,
      "budget_violations": [
        "Token limit exceeded: 21123 > 16384",
        "Turn limit exceeded: 6 >= 6"
      ],
      "refs_cited": []
    },
    "retrieved_ref_ids": [],
    "valid_ref_ids": []
  },
  {
    "question": {
      "question_id": "cs03_q18_temporal",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 15,
      "question_type": "temporal",
      "prompt": "When did the first hepatic enzyme elevations appear relative to drug exposure initiation?",
      "ground_truth": {
        "canonical_answer": "Hepatic enzyme elevations first appeared during the early signal phase, approximately weeks 9-10 of the trial, several weeks after subjects began receiving LNS-4821 with concomitant statin therapy.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_010",
          "clinical_signal_03_ep_013"
        ],
        "key_facts": [
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases",
          "multi-site signal distribution rules out site-specific confounders as causal explanation",
          "ALT elevations appeared progressively over multiple weeks of statin co-administration with onset timing correlating with cumulative exposure duration rather than a single acute event"
        ]
      }
    },
    "answer": {
      "question_id": "cs03_q18_temporal",
      "answer_text": "The provided search results do not contain information about the timing of the first hepatic enzyme elevations relative to drug exposure initiation. The documents retrieved are daily operations summaries focusing on enrollment numbers, site-specific data, and concomitant medication use (e.g., statins), but none mention hepatic enzyme elevations or laboratory findings related to liver function [clinical_signal_03_ep_011], [clinical_signal_03_ep_015], [clinical_signal_03_ep_009], [clinical_signal_03_ep_013], [clinical_signal_03_ep_012].\n\nTherefore, based on the available data, the time of first hepatic enzyme elevations relative to drug initiation cannot be determined.",
      "turns": [
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_868611acfc0f40509a63eff5",
              "name": "memory_capabilities",
              "arguments": {}
            }
          ],
          "tokens_used": 749
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_868611acfc0f40509a63eff5",
              "content": "{\"search_modes\": [\"keyword\", \"semantic\"], \"filter_fields\": [{\"name\": \"scope_id\", \"field_type\": \"string\", \"description\": \"Filter by scope ID\", \"enum_values\": null}, {\"name\": \"start_date\", \"field_type\": \"string\", \"description\": \"Filter episodes after this ISO date\", \"enum_values\": null}, {\"name\": \"end_date\", \"field_type\": \"string\", \"description\": \"Filter episodes before this ISO date\", \"enum_values\": null}], \"max_results_per_search\": 7, \"supports_date_range\": true, \"extra_tools\": [{\"name\": \"batch_retrieve\", \"description\": \"Retrieve multiple full documents by their reference IDs in a single call. PREFER this over calling memory_retrieve multiple times \\u2014 it is far more efficient and uses only one tool call instead of one per document. After memory_search, pass all ref_ids you want to read to this tool.\", \"parameters\": {\"type\": \"object\", \"properties\": {\"ref_ids\": {\"type\": \"array\", \"items\": {\"type\": \"string\"}, \"description\": \"List of reference IDs to retrieve (from search results).\"}}, \"required\": [\"ref_ids\"]}}]}",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_47b692b77e4346f3802fa447",
              "name": "memory_search",
              "arguments": {
                "query": "first hepatic enzyme elevations after drug exposure initiation",
                "limit": 7
              }
            }
          ],
          "tokens_used": 1052
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_47b692b77e4346f3802fa447",
              "content": "[{\"ref_id\": \"clinical_signal_03_ep_011\", \"text\": \"## 2024-05-13 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 189\\n- Active: 182\\n- Screen Failures Cumulative: 27\\n- Withdrawals Cumulative: 7\\n\\n#### Sites\\n- Site 01\\n  - Enrolled: 19\\n  - Active: 19\\n  - Statin Concomitant: 5\\n- Site 02\\n  - Enrolled: 14\\n  - Active: 14\\n  - Statin Concomitant: 3\\n- Site 03\\n  - Enrolled: 17\\n  - Active: 17\\n  - Statin Concomitant: 5\\n- Site 04\\n  - Enrolled: 12\\n  - Active: 12\\n  - Statin Concomitant: 3\\n- Site 05\\n  - Enrolled: 16\\n  - Active: 16\\n  - Statin Concomita\", \"score\": 0.031746031746031744, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_015\", \"text\": \"## 2024-06-10 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 215\\n- Active: 208\\n- Screen Failures Cumulative: 33\\n- Withdrawals Cumulative: 7\\n\\n#### Sites\\n- Site 01 Enrolled: 22\\n- Site 01 Active: 22\\n- Site 01 Statin Concomitant: 5\\n- Site 02 Enrolled: 16\\n- Site 02 Active: 16\\n- Site 02 Statin Concomitant: 4\\n- Site 03 Enrolled: 20\\n- Site 03 Active: 20\\n- Site 03 Statin Concomitant: 5\\n- Site 04 Enrolled: 14\\n- Site 04 Active: 14\\n- Site 04 Statin Concomitant: 3\\n- Site 05 Enrolled: 18\\n- Site \", \"score\": 0.031054405392392875, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_013\", \"text\": \"## 2024-05-27 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 195\\n- Active: 191\\n- Screen Failures Cumulative: 29\\n- Withdrawals Cumulative: 4\\n\\n#### Sites\\n- Site 01\\n  - Enrolled: 19\\n  - Active: 19\\n  - Statin Concomitant: 5\\n- Site 02\\n  - Enrolled: 14\\n  - Active: 14\\n  - Statin Concomitant: 4\\n- Site 03\\n  - Enrolled: 18\\n  - Active: 18\\n  - Statin Concomitant: 5\\n- Site 04\\n  - Enrolled: 13\\n  - Active: 13\\n  - Statin Concomitant: 4\\n- Site 05\\n  - Enrolled: 16\\n  - Active: 16\\n  - Statin Concomita\", \"score\": 0.030886196246139225, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_009\", \"text\": \"## 2024-04-29 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 185\\n- Active: 180\\n- Screen Failures Cumulative: 22\\n- Withdrawals Cumulative: 5\\n\\n#### Sites\\n- Site 01 Enrolled: 18\\n- Site 01 Active: 18\\n- Site 01 Statin Concomitant: 5\\n- Site 02 Enrolled: 14\\n- Site 02 Active: 14\\n- Site 02 Statin Concomitant: 4\\n- Site 03 Enrolled: 17\\n- Site 03 Active: 17\\n- Site 03 Statin Concomitant: 4\\n- Site 04 Enrolled: 12\\n- Site 04 Active: 12\\n- Site 04 Statin Concomitant: 3\\n- Site 05 Enrolled: 15\\n- Site \", \"score\": 0.0304147465437788, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_002\", \"text\": \"## 2024-03-11 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 60\\n- Active: 60\\n- Screen Failures Cumulative: 4\\n- Withdrawals Cumulative: 0\\n\\n#### Sites\\n- Site 01 Enrolled: 6\\n- Site 01 Active: 6\\n- Site 01 Statin Concomitant: 1\\n- Site 02 Enrolled: 4\\n- Site 02 Active: 4\\n- Site 02 Statin Concomitant: 1\\n- Site 03 Enrolled: 5\\n- Site 03 Active: 5\\n- Site 03 Statin Concomitant: 1\\n- Site 04 Enrolled: 4\\n- Site 04 Active: 4\\n- Site 04 Statin Concomitant: 1\\n- Site 05 Enrolled: 5\\n- Site 05 Active: 5\", \"score\": 0.030309988518943745, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_001\", \"text\": \"## 2024-03-04 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 40\\n- Active: 40\\n- Screen Failures Cumulative: 2\\n- Withdrawals Cumulative: 0\\n\\n#### Sites\\n- Site 01: \\n  - Enrolled: 4\\n  - Active: 4\\n  - Statin Concomitant: 1\\n- Site 02: \\n  - Enrolled: 3\\n  - Active: 3\\n  - Statin Concomitant: 0\\n- Site 03: \\n  - Enrolled: 3\\n  - Active: 3\\n  - Statin Concomitant: 0\\n- Site 04: \\n  - Enrolled: 2\\n  - Active: 2\\n  - Statin Concomitant: 0\\n- Site 05: \\n  - Enrolled: 3\\n  - Active: 3\\n  - Statin Concomitant:\", \"score\": 0.03028233151183971, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_012\", \"text\": \"## 2024-05-20 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 192\\n- Active: 186\\n- Screen Failures Cumulative: 21\\n- Withdrawals Cumulative: 6\\n\\n#### Sites\\n- Site 01\\n  - Enrolled: 19\\n  - Active: 19\\n  - Statin Concomitant: 5\\n- Site 02\\n  - Enrolled: 14\\n  - Active: 14\\n  - Statin Concomitant: 3\\n- Site 03\\n  - Enrolled: 18\\n  - Active: 18\\n  - Statin Concomitant: 5\\n- Site 04\\n  - Enrolled: 13\\n  - Active: 13\\n  - Statin Concomitant: 3\\n- Site 05\\n  - Enrolled: 16\\n  - Active: 16\\n  - Statin Concomita\", \"score\": 0.029857397504456328, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_7ce30c3000144cf7bb510973",
              "name": "memory_search",
              "arguments": {
                "query": "hepatic enzyme elevations onset time after drug initiation",
                "limit": 7
              }
            }
          ],
          "tokens_used": 3169
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_7ce30c3000144cf7bb510973",
              "content": "[{\"ref_id\": \"clinical_signal_03_ep_011\", \"text\": \"## 2024-05-13 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 189\\n- Active: 182\\n- Screen Failures Cumulative: 27\\n- Withdrawals Cumulative: 7\\n\\n#### Sites\\n- Site 01\\n  - Enrolled: 19\\n  - Active: 19\\n  - Statin Concomitant: 5\\n- Site 02\\n  - Enrolled: 14\\n  - Active: 14\\n  - Statin Concomitant: 3\\n- Site 03\\n  - Enrolled: 17\\n  - Active: 17\\n  - Statin Concomitant: 5\\n- Site 04\\n  - Enrolled: 12\\n  - Active: 12\\n  - Statin Concomitant: 3\\n- Site 05\\n  - Enrolled: 16\\n  - Active: 16\\n  - Statin Concomita\", \"score\": 0.03125763125763126, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_015\", \"text\": \"## 2024-06-10 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 215\\n- Active: 208\\n- Screen Failures Cumulative: 33\\n- Withdrawals Cumulative: 7\\n\\n#### Sites\\n- Site 01 Enrolled: 22\\n- Site 01 Active: 22\\n- Site 01 Statin Concomitant: 5\\n- Site 02 Enrolled: 16\\n- Site 02 Active: 16\\n- Site 02 Statin Concomitant: 4\\n- Site 03 Enrolled: 20\\n- Site 03 Active: 20\\n- Site 03 Statin Concomitant: 5\\n- Site 04 Enrolled: 14\\n- Site 04 Active: 14\\n- Site 04 Statin Concomitant: 3\\n- Site 05 Enrolled: 18\\n- Site \", \"score\": 0.030834914611005692, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_009\", \"text\": \"## 2024-04-29 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 185\\n- Active: 180\\n- Screen Failures Cumulative: 22\\n- Withdrawals Cumulative: 5\\n\\n#### Sites\\n- Site 01 Enrolled: 18\\n- Site 01 Active: 18\\n- Site 01 Statin Concomitant: 5\\n- Site 02 Enrolled: 14\\n- Site 02 Active: 14\\n- Site 02 Statin Concomitant: 4\\n- Site 03 Enrolled: 17\\n- Site 03 Active: 17\\n- Site 03 Statin Concomitant: 4\\n- Site 04 Enrolled: 12\\n- Site 04 Active: 12\\n- Site 04 Statin Concomitant: 3\\n- Site 05 Enrolled: 15\\n- Site \", \"score\": 0.030679156908665108, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_013\", \"text\": \"## 2024-05-27 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 195\\n- Active: 191\\n- Screen Failures Cumulative: 29\\n- Withdrawals Cumulative: 4\\n\\n#### Sites\\n- Site 01\\n  - Enrolled: 19\\n  - Active: 19\\n  - Statin Concomitant: 5\\n- Site 02\\n  - Enrolled: 14\\n  - Active: 14\\n  - Statin Concomitant: 4\\n- Site 03\\n  - Enrolled: 18\\n  - Active: 18\\n  - Statin Concomitant: 5\\n- Site 04\\n  - Enrolled: 13\\n  - Active: 13\\n  - Statin Concomitant: 4\\n- Site 05\\n  - Enrolled: 16\\n  - Active: 16\\n  - Statin Concomita\", \"score\": 0.030621785881252923, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_012\", \"text\": \"## 2024-05-20 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 192\\n- Active: 186\\n- Screen Failures Cumulative: 21\\n- Withdrawals Cumulative: 6\\n\\n#### Sites\\n- Site 01\\n  - Enrolled: 19\\n  - Active: 19\\n  - Statin Concomitant: 5\\n- Site 02\\n  - Enrolled: 14\\n  - Active: 14\\n  - Statin Concomitant: 3\\n- Site 03\\n  - Enrolled: 18\\n  - Active: 18\\n  - Statin Concomitant: 5\\n- Site 04\\n  - Enrolled: 13\\n  - Active: 13\\n  - Statin Concomitant: 3\\n- Site 05\\n  - Enrolled: 16\\n  - Active: 16\\n  - Statin Concomita\", \"score\": 0.03057889822595705, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_001\", \"text\": \"## 2024-03-04 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 40\\n- Active: 40\\n- Screen Failures Cumulative: 2\\n- Withdrawals Cumulative: 0\\n\\n#### Sites\\n- Site 01: \\n  - Enrolled: 4\\n  - Active: 4\\n  - Statin Concomitant: 1\\n- Site 02: \\n  - Enrolled: 3\\n  - Active: 3\\n  - Statin Concomitant: 0\\n- Site 03: \\n  - Enrolled: 3\\n  - Active: 3\\n  - Statin Concomitant: 0\\n- Site 04: \\n  - Enrolled: 2\\n  - Active: 2\\n  - Statin Concomitant: 0\\n- Site 05: \\n  - Enrolled: 3\\n  - Active: 3\\n  - Statin Concomitant:\", \"score\": 0.03028233151183971, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_008\", \"text\": \"## 2024-04-22 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 180\\n- Active: 177\\n- Screen Failures Cumulative: 13\\n- Withdrawals Cumulative: 3\\n\\n#### Sites\\n- Site 01 Enrolled: 18\\n- Site 01 Active: 18\\n- Site 01 Statin Concomitant: 5\\n- Site 02 Enrolled: 13\\n- Site 02 Active: 13\\n- Site 02 Statin Concomitant: 3\\n- Site 03 Enrolled: 16\\n- Site 03 Active: 16\\n- Site 03 Statin Concomitant: 4\\n- Site 04 Enrolled: 12\\n- Site 04 Active: 12\\n- Site 04 Statin Concomitant: 3\\n- Site 05 Enrolled: 15\\n- Site \", \"score\": 0.029910714285714284, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_67867bdb37ba443689f5f23f",
              "name": "memory_search",
              "arguments": {
                "query": "first hepatic enzyme elevations after drug start",
                "limit": 7
              }
            }
          ],
          "tokens_used": 5289
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_67867bdb37ba443689f5f23f",
              "content": "[{\"ref_id\": \"clinical_signal_03_ep_011\", \"text\": \"## 2024-05-13 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 189\\n- Active: 182\\n- Screen Failures Cumulative: 27\\n- Withdrawals Cumulative: 7\\n\\n#### Sites\\n- Site 01\\n  - Enrolled: 19\\n  - Active: 19\\n  - Statin Concomitant: 5\\n- Site 02\\n  - Enrolled: 14\\n  - Active: 14\\n  - Statin Concomitant: 3\\n- Site 03\\n  - Enrolled: 17\\n  - Active: 17\\n  - Statin Concomitant: 5\\n- Site 04\\n  - Enrolled: 12\\n  - Active: 12\\n  - Statin Concomitant: 3\\n- Site 05\\n  - Enrolled: 16\\n  - Active: 16\\n  - Statin Concomita\", \"score\": 0.03200204813108039, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_015\", \"text\": \"## 2024-06-10 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 215\\n- Active: 208\\n- Screen Failures Cumulative: 33\\n- Withdrawals Cumulative: 7\\n\\n#### Sites\\n- Site 01 Enrolled: 22\\n- Site 01 Active: 22\\n- Site 01 Statin Concomitant: 5\\n- Site 02 Enrolled: 16\\n- Site 02 Active: 16\\n- Site 02 Statin Concomitant: 4\\n- Site 03 Enrolled: 20\\n- Site 03 Active: 20\\n- Site 03 Statin Concomitant: 5\\n- Site 04 Enrolled: 14\\n- Site 04 Active: 14\\n- Site 04 Statin Concomitant: 3\\n- Site 05 Enrolled: 18\\n- Site \", \"score\": 0.030834914611005692, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_001\", \"text\": \"## 2024-03-04 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 40\\n- Active: 40\\n- Screen Failures Cumulative: 2\\n- Withdrawals Cumulative: 0\\n\\n#### Sites\\n- Site 01: \\n  - Enrolled: 4\\n  - Active: 4\\n  - Statin Concomitant: 1\\n- Site 02: \\n  - Enrolled: 3\\n  - Active: 3\\n  - Statin Concomitant: 0\\n- Site 03: \\n  - Enrolled: 3\\n  - Active: 3\\n  - Statin Concomitant: 0\\n- Site 04: \\n  - Enrolled: 2\\n  - Active: 2\\n  - Statin Concomitant: 0\\n- Site 05: \\n  - Enrolled: 3\\n  - Active: 3\\n  - Statin Concomitant:\", \"score\": 0.030679156908665108, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_009\", \"text\": \"## 2024-04-29 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 185\\n- Active: 180\\n- Screen Failures Cumulative: 22\\n- Withdrawals Cumulative: 5\\n\\n#### Sites\\n- Site 01 Enrolled: 18\\n- Site 01 Active: 18\\n- Site 01 Statin Concomitant: 5\\n- Site 02 Enrolled: 14\\n- Site 02 Active: 14\\n- Site 02 Statin Concomitant: 4\\n- Site 03 Enrolled: 17\\n- Site 03 Active: 17\\n- Site 03 Statin Concomitant: 4\\n- Site 04 Enrolled: 12\\n- Site 04 Active: 12\\n- Site 04 Statin Concomitant: 3\\n- Site 05 Enrolled: 15\\n- Site \", \"score\": 0.030679156908665108, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_013\", \"text\": \"## 2024-05-27 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 195\\n- Active: 191\\n- Screen Failures Cumulative: 29\\n- Withdrawals Cumulative: 4\\n\\n#### Sites\\n- Site 01\\n  - Enrolled: 19\\n  - Active: 19\\n  - Statin Concomitant: 5\\n- Site 02\\n  - Enrolled: 14\\n  - Active: 14\\n  - Statin Concomitant: 4\\n- Site 03\\n  - Enrolled: 18\\n  - Active: 18\\n  - Statin Concomitant: 5\\n- Site 04\\n  - Enrolled: 13\\n  - Active: 13\\n  - Statin Concomitant: 4\\n- Site 05\\n  - Enrolled: 16\\n  - Active: 16\\n  - Statin Concomita\", \"score\": 0.030117753623188408, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_012\", \"text\": \"## 2024-05-20 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 192\\n- Active: 186\\n- Screen Failures Cumulative: 21\\n- Withdrawals Cumulative: 6\\n\\n#### Sites\\n- Site 01\\n  - Enrolled: 19\\n  - Active: 19\\n  - Statin Concomitant: 5\\n- Site 02\\n  - Enrolled: 14\\n  - Active: 14\\n  - Statin Concomitant: 3\\n- Site 03\\n  - Enrolled: 18\\n  - Active: 18\\n  - Statin Concomitant: 5\\n- Site 04\\n  - Enrolled: 13\\n  - Active: 13\\n  - Statin Concomitant: 3\\n- Site 05\\n  - Enrolled: 16\\n  - Active: 16\\n  - Statin Concomita\", \"score\": 0.030090497737556562, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_002\", \"text\": \"## 2024-03-11 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 60\\n- Active: 60\\n- Screen Failures Cumulative: 4\\n- Withdrawals Cumulative: 0\\n\\n#### Sites\\n- Site 01 Enrolled: 6\\n- Site 01 Active: 6\\n- Site 01 Statin Concomitant: 1\\n- Site 02 Enrolled: 4\\n- Site 02 Active: 4\\n- Site 02 Statin Concomitant: 1\\n- Site 03 Enrolled: 5\\n- Site 03 Active: 5\\n- Site 03 Statin Concomitant: 1\\n- Site 04 Enrolled: 4\\n- Site 04 Active: 4\\n- Site 04 Statin Concomitant: 1\\n- Site 05 Enrolled: 5\\n- Site 05 Active: 5\", \"score\": 0.03007688828584351, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "The provided search results do not contain information about the timing of the first hepatic enzyme elevations relative to drug exposure initiation. The documents retrieved are daily operations summaries focusing on enrollment numbers, site-specific data, and concomitant medication use (e.g., statins), but none mention hepatic enzyme elevations or laboratory findings related to liver function [clinical_signal_03_ep_011], [clinical_signal_03_ep_015], [clinical_signal_03_ep_009], [clinical_signal_03_ep_013], [clinical_signal_03_ep_012].\n\nTherefore, based on the available data, the time of first hepatic enzyme elevations relative to drug initiation cannot be determined.",
          "tokens_used": 7526
        }
      ],
      "tool_calls_made": 4,
      "total_tokens": 17785,
      "wall_time_ms": 10050.986050046049,
      "budget_violations": [
        "Token limit exceeded: 17785 > 16384"
      ],
      "refs_cited": [
        "clinical_signal_03_ep_011",
        "clinical_signal_03_ep_015",
        "clinical_signal_03_ep_009",
        "clinical_signal_03_ep_013",
        "clinical_signal_03_ep_012"
      ]
    },
    "retrieved_ref_ids": [
      "clinical_signal_03_ep_011",
      "clinical_signal_03_ep_015",
      "clinical_signal_03_ep_009",
      "clinical_signal_03_ep_013",
      "clinical_signal_03_ep_012"
    ],
    "valid_ref_ids": [
      "clinical_signal_03_ep_011",
      "clinical_signal_03_ep_015",
      "clinical_signal_03_ep_009",
      "clinical_signal_03_ep_013",
      "clinical_signal_03_ep_012"
    ]
  },
  {
    "question": {
      "question_id": "cs03_q19_distractor",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 15,
      "question_type": "distractor_resistance",
      "prompt": "Are novel urinary biomarkers (KIM-1, NGAL) showing any abnormalities in trial subjects?",
      "ground_truth": {
        "canonical_answer": "No. Renal biomarkers remain within normal limits. The emerging safety signal is hepatic (ALT/AST elevation), not renal.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_004",
          "clinical_signal_03_ep_011"
        ],
        "key_facts": [
          "the adverse signal is hepatic (ALT/AST elevation), not renal \u2014 kidney function markers remain stable while liver enzymes diverge",
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases"
        ]
      }
    },
    "answer": {
      "question_id": "cs03_q19_distractor",
      "answer_text": "The retrieved documents do not contain any data on novel urinary biomarkers such as KIM-1 (Kidney Injury Molecule-1) or NGAL (Neutrophil Gelatinase-Associated Lipocalin). The available information focuses on standard lab panels (e.g., ALT, AST, creatinine, BUN) and enrollment metrics across trial sites, but there is no mention of urinary biomarker measurements or abnormalities related to KIM-1 or NGAL in the trial subjects [clinical_signal_03_ep_004], [clinical_signal_03_ep_014], [clinical_signal_03_ep_005], [clinical_signal_03_ep_011], [clinical_signal_03_ep_003], [clinical_signal_03_ep_002], [clinical_signal_03_ep_001].\n\nTherefore, based on the current evidence, it is not possible to determine whether KIM-1 or NGAL are showing abnormalities in trial subjects.",
      "turns": [
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_40e14dec966e42dfa0b4c7ed",
              "name": "memory_capabilities",
              "arguments": {}
            }
          ],
          "tokens_used": 754
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_40e14dec966e42dfa0b4c7ed",
              "content": "{\"search_modes\": [\"keyword\", \"semantic\"], \"filter_fields\": [{\"name\": \"scope_id\", \"field_type\": \"string\", \"description\": \"Filter by scope ID\", \"enum_values\": null}, {\"name\": \"start_date\", \"field_type\": \"string\", \"description\": \"Filter episodes after this ISO date\", \"enum_values\": null}, {\"name\": \"end_date\", \"field_type\": \"string\", \"description\": \"Filter episodes before this ISO date\", \"enum_values\": null}], \"max_results_per_search\": 7, \"supports_date_range\": true, \"extra_tools\": [{\"name\": \"batch_retrieve\", \"description\": \"Retrieve multiple full documents by their reference IDs in a single call. PREFER this over calling memory_retrieve multiple times \\u2014 it is far more efficient and uses only one tool call instead of one per document. After memory_search, pass all ref_ids you want to read to this tool.\", \"parameters\": {\"type\": \"object\", \"properties\": {\"ref_ids\": {\"type\": \"array\", \"items\": {\"type\": \"string\"}, \"description\": \"List of reference IDs to retrieve (from search results).\"}}, \"required\": [\"ref_ids\"]}}]}",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_83f4cfbc754243f8b3a23b3c",
              "name": "memory_search",
              "arguments": {
                "query": "novel urinary biomarkers KIM-1 NGAL abnormalities trial subjects",
                "limit": 7
              }
            }
          ],
          "tokens_used": 1061
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_83f4cfbc754243f8b3a23b3c",
              "content": "[{\"ref_id\": \"clinical_signal_03_ep_014\", \"text\": \"## 2024-06-03 Daily Operations Summary\\n### Lab Panels\\n#### Statin Subgroup\\n- N: 53\\n- ALT (U/L) Mean: 57.6\\n- ALT (U/L) Median: 56.0\\n- AST (U/L) Mean: 45.7\\n- AST (U/L) Median: 45.7\\n- Bilirubin (mg/dL) Mean: 0.86\\n- Bilirubin (mg/dL) Median: 0.83\\n- ALP (U/L) Mean: 65.4\\n- ALP (U/L) Median: 57.0\\n- Creatinine (mg/dL) Mean: 0.89\\n- Creatinine (mg/dL) Median: 0.85\\n- BUN (mg/dL) Mean: 14.7\\n- BUN (mg/dL) Median: 13.1\\n- WBC (K) Mean: 6.2\\n- WBC (K) Median: 7.0\\n- Platelets (K) Mean: 223\\n- Platelets (K) Median:\", \"score\": 0.03278688524590164, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_005\", \"text\": \"## 2024-04-01 Daily Operations Summary\\n### Lab Panels\\n#### Statin Subgroup\\n- N: 56\\n- ALT (U/L) Mean: 26.3\\n- ALT (U/L) Median: 25.5\\n- AST (U/L) Mean: 22.6\\n- AST (U/L) Median: 22.4\\n- Bilirubin (mg/dL) Mean: 0.67\\n- Bilirubin (mg/dL) Median: 0.65\\n- ALP (U/L) Mean: 68.6\\n- ALP (U/L) Median: 79.7\\n- Creatinine (mg/dL) Mean: 1.02\\n- Creatinine (mg/dL) Median: 0.97\\n- BUN (mg/dL) Mean: 17.6\\n- BUN (mg/dL) Median: 11.1\\n- WBC (K) Mean: 6.2\\n- WBC (K) Median: 6.1\\n- Platelets (K) Mean: 258\\n- Platelets (K) Median:\", \"score\": 0.03252247488101534, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_004\", \"text\": \"## 2024-03-25 Daily Operations Summary\\n### Lab Panels\\n#### Statin Subgroup\\n- N: 52\\n- ALT (U/L) Mean: 24.6\\n- ALT (U/L) Median: 23.8\\n- AST (U/L) Mean: 23.6\\n- AST (U/L) Median: 23.2\\n- Bilirubin (mg/dL) Mean: 0.86\\n- Bilirubin (mg/dL) Median: 0.84\\n- ALP (U/L) Mean: 73.7\\n- ALP (U/L) Median: 63.8\\n- Creatinine (mg/dL) Mean: 1.06\\n- Creatinine (mg/dL) Median: 0.92\\n- BUN (mg/dL) Mean: 13.3\\n- BUN (mg/dL) Median: 13.0\\n- WBC (K) Mean: 8.2\\n- WBC (K) Median: 5.5\\n- Platelets (K) Mean: 235\\n- Platelets (K) Median:\", \"score\": 0.032266458495966696, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_003\", \"text\": \"## 2024-03-18 Daily Operations Summary\\n### Lab Panels\\n- Statin Subgroup N: 55\\n- Statin Subgroup ALT (U/L) Mean: 26.0\\n- Statin Subgroup ALT (U/L) Median: 24.3\\n- Statin Subgroup AST (U/L) Mean: 27.9\\n- Statin Subgroup AST (U/L) Median: 25.9\\n- Statin Subgroup Bilirubin (mg/dL) Mean: 0.59\\n- Statin Subgroup Bilirubin (mg/dL) Median: 0.56\\n- Statin Subgroup ALP (U/L) Mean: 79.3\\n- Statin Subgroup ALP (U/L) Median: 57.2\\n- Statin Subgroup Creatinine (mg/dL) Mean: 1.04\\n- Statin Subgroup Creatinine (mg/dL) M\", \"score\": 0.032018442622950824, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_002\", \"text\": \"## 2024-03-11 Daily Operations Summary\\n### Lab Panels\\n- Statin Subgroup N: 53\\n- Statin Subgroup ALT (U/L) Mean: 26.8\\n- Statin Subgroup ALT (U/L) Median: 26.3\\n- Statin Subgroup AST (U/L) Mean: 22.1\\n- Statin Subgroup AST (U/L) Median: 20.8\\n- Statin Subgroup Bilirubin (mg/dL) Mean: 0.73\\n- Statin Subgroup Bilirubin (mg/dL) Median: 0.72\\n- Statin Subgroup ALP (U/L) Mean: 71.0\\n- Statin Subgroup ALP (U/L) Median: 75.0\\n- Statin Subgroup Creatinine (mg/dL) Mean: 0.85\\n- Statin Subgroup Creatinine (mg/dL) M\", \"score\": 0.03177805800756621, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_015\", \"text\": \"## 2024-06-10 Daily Operations Summary\\n### Lab Panels\\n#### Statin Subgroup\\n- N: 54\\n- ALT (U/L) Mean: 62.2\\n- ALT (U/L) Median: 61.3\\n- AST (U/L) Mean: 51.0\\n- AST (U/L) Median: 50.3\\n- Bilirubin (mg/dL) Mean: 0.89\\n- Bilirubin (mg/dL) Median: 0.86\\n- ALP (U/L) Mean: 58.6\\n- ALP (U/L) Median: 78.4\\n- Creatinine (mg/dL) Mean: 0.97\\n- Creatinine (mg/dL) Median: 0.8\\n- BUN (mg/dL) Mean: 14.8\\n- BUN (mg/dL) Median: 16.3\\n- WBC (K) Mean: 6.4\\n- WBC (K) Median: 7.9\\n- Platelets (K) Mean: 241\\n- Platelets (K) Median: \", \"score\": 0.031544957774465976, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_001\", \"text\": \"## 2024-03-04 Daily Operations Summary\\n### Lab Panels\\n- Statin Subgroup:\\n  - N: 53\\n  - ALT (U/L) Mean: 25.5\\n  - ALT (U/L) Median: 22.7\\n  - AST (U/L) Mean: 26.4\\n  - AST (U/L) Median: 24.4\\n  - Bilirubin (mg/dL) Mean: 0.78\\n  - Bilirubin (mg/dL) Median: 0.74\\n  - ALP (U/L) Mean: 84.9\\n  - ALP (U/L) Median: 76.7\\n  - Creatinine (mg/dL) Mean: 1.06\\n  - Creatinine (mg/dL) Median: 0.95\\n  - BUN (mg/dL) Mean: 16.9\\n  - BUN (mg/dL) Median: 15.1\\n  - WBC (K) Mean: 5.9\\n  - WBC (K) Median: 7.6\\n  - Platelets (K) Mea\", \"score\": 0.03131881575727918, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_3533791b24c04ad58919c470",
              "name": "memory_search",
              "arguments": {
                "query": "urinary biomarkers KIM-1 NGAL trial data",
                "limit": 7
              }
            }
          ],
          "tokens_used": 3365
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_3533791b24c04ad58919c470",
              "content": "[{\"ref_id\": \"clinical_signal_03_ep_004\", \"text\": \"## 2024-03-25 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 100\\n- Active: 98\\n- Screen Failures Cumulative: 11\\n- Withdrawals Cumulative: 2\\n\\n#### Sites\\n- Site 01\\n  - Enrolled: 10\\n  - Active: 10\\n  - Statin Concomitant: 2\\n- Site 02\\n  - Enrolled: 7\\n  - Active: 7\\n  - Statin Concomitant: 1\\n- Site 03\\n  - Enrolled: 9\\n  - Active: 9\\n  - Statin Concomitant: 2\\n- Site 04\\n  - Enrolled: 6\\n  - Active: 6\\n  - Statin Concomitant: 1\\n- Site 05\\n  - Enrolled: 8\\n  - Active: 8\\n  - Statin Concomitant: 2\\n- S\", \"score\": 0.03200204813108039, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_014\", \"text\": \"## 2024-06-03 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 192\\n- Active: 182\\n- Screen Failures Cumulative: 28\\n- Withdrawals Cumulative: 10\\n\\n#### Sites\\n- Site 01 Enrolled: 19\\n- Site 01 Active: 19\\n- Site 01 Statin Concomitant: 5\\n- Site 02 Enrolled: 14\\n- Site 02 Active: 14\\n- Site 02 Statin Concomitant: 4\\n- Site 03 Enrolled: 18\\n- Site 03 Active: 18\\n- Site 03 Statin Concomitant: 4\\n- Site 04 Enrolled: 13\\n- Site 04 Active: 13\\n- Site 04 Statin Concomitant: 3\\n- Site 05 Enrolled: 16\\n- Site\", \"score\": 0.031754032258064516, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_005\", \"text\": \"## 2024-04-01 Daily Operations Summary\\n### Lab Panels\\n#### Statin Subgroup\\n- N: 56\\n- ALT (U/L) Mean: 26.3\\n- ALT (U/L) Median: 25.5\\n- AST (U/L) Mean: 22.6\\n- AST (U/L) Median: 22.4\\n- Bilirubin (mg/dL) Mean: 0.67\\n- Bilirubin (mg/dL) Median: 0.65\\n- ALP (U/L) Mean: 68.6\\n- ALP (U/L) Median: 79.7\\n- Creatinine (mg/dL) Mean: 1.02\\n- Creatinine (mg/dL) Median: 0.97\\n- BUN (mg/dL) Mean: 17.6\\n- BUN (mg/dL) Median: 11.1\\n- WBC (K) Mean: 6.2\\n- WBC (K) Median: 6.1\\n- Platelets (K) Mean: 258\\n- Platelets (K) Median:\", \"score\": 0.031544957774465976, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_011\", \"text\": \"## 2024-05-13 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 189\\n- Active: 182\\n- Screen Failures Cumulative: 27\\n- Withdrawals Cumulative: 7\\n\\n#### Sites\\n- Site 01\\n  - Enrolled: 19\\n  - Active: 19\\n  - Statin Concomitant: 5\\n- Site 02\\n  - Enrolled: 14\\n  - Active: 14\\n  - Statin Concomitant: 3\\n- Site 03\\n  - Enrolled: 17\\n  - Active: 17\\n  - Statin Concomitant: 5\\n- Site 04\\n  - Enrolled: 12\\n  - Active: 12\\n  - Statin Concomitant: 3\\n- Site 05\\n  - Enrolled: 16\\n  - Active: 16\\n  - Statin Concomita\", \"score\": 0.030886196246139225, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_003\", \"text\": \"## 2024-03-18 Daily Operations Summary\\n### Lab Panels\\n- Statin Subgroup N: 55\\n- Statin Subgroup ALT (U/L) Mean: 26.0\\n- Statin Subgroup ALT (U/L) Median: 24.3\\n- Statin Subgroup AST (U/L) Mean: 27.9\\n- Statin Subgroup AST (U/L) Median: 25.9\\n- Statin Subgroup Bilirubin (mg/dL) Mean: 0.59\\n- Statin Subgroup Bilirubin (mg/dL) Median: 0.56\\n- Statin Subgroup ALP (U/L) Mean: 79.3\\n- Statin Subgroup ALP (U/L) Median: 57.2\\n- Statin Subgroup Creatinine (mg/dL) Mean: 1.04\\n- Statin Subgroup Creatinine (mg/dL) M\", \"score\": 0.030776515151515152, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_002\", \"text\": \"## 2024-03-11 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 60\\n- Active: 60\\n- Screen Failures Cumulative: 4\\n- Withdrawals Cumulative: 0\\n\\n#### Sites\\n- Site 01 Enrolled: 6\\n- Site 01 Active: 6\\n- Site 01 Statin Concomitant: 1\\n- Site 02 Enrolled: 4\\n- Site 02 Active: 4\\n- Site 02 Statin Concomitant: 1\\n- Site 03 Enrolled: 5\\n- Site 03 Active: 5\\n- Site 03 Statin Concomitant: 1\\n- Site 04 Enrolled: 4\\n- Site 04 Active: 4\\n- Site 04 Statin Concomitant: 1\\n- Site 05 Enrolled: 5\\n- Site 05 Active: 5\", \"score\": 0.03076923076923077, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_001\", \"text\": \"## 2024-03-04 Daily Operations Summary\\n### Lab Panels\\n- Statin Subgroup:\\n  - N: 53\\n  - ALT (U/L) Mean: 25.5\\n  - ALT (U/L) Median: 22.7\\n  - AST (U/L) Mean: 26.4\\n  - AST (U/L) Median: 24.4\\n  - Bilirubin (mg/dL) Mean: 0.78\\n  - Bilirubin (mg/dL) Median: 0.74\\n  - ALP (U/L) Mean: 84.9\\n  - ALP (U/L) Median: 76.7\\n  - Creatinine (mg/dL) Mean: 1.06\\n  - Creatinine (mg/dL) Median: 0.95\\n  - BUN (mg/dL) Mean: 16.9\\n  - BUN (mg/dL) Median: 15.1\\n  - WBC (K) Mean: 5.9\\n  - WBC (K) Median: 7.6\\n  - Platelets (K) Mea\", \"score\": 0.030303030303030304, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_c31a71ac6ee04617950a93ce",
              "name": "batch_retrieve",
              "arguments": {
                "ref_ids": [
                  "clinical_signal_03_ep_004",
                  "clinical_signal_03_ep_014",
                  "clinical_signal_03_ep_005",
                  "clinical_signal_03_ep_011",
                  "clinical_signal_03_ep_003",
                  "clinical_signal_03_ep_002",
                  "clinical_signal_03_ep_001"
                ]
              }
            }
          ],
          "tokens_used": 5622
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_c31a71ac6ee04617950a93ce",
              "content": "[Context budget exhausted \u2014 synthesize answer from evidence already retrieved]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "The retrieved documents do not contain any data on novel urinary biomarkers such as KIM-1 (Kidney Injury Molecule-1) or NGAL (Neutrophil Gelatinase-Associated Lipocalin). The available information focuses on standard lab panels (e.g., ALT, AST, creatinine, BUN) and enrollment metrics across trial sites, but there is no mention of urinary biomarker measurements or abnormalities related to KIM-1 or NGAL in the trial subjects [clinical_signal_03_ep_004], [clinical_signal_03_ep_014], [clinical_signal_03_ep_005], [clinical_signal_03_ep_011], [clinical_signal_03_ep_003], [clinical_signal_03_ep_002], [clinical_signal_03_ep_001].\n\nTherefore, based on the current evidence, it is not possible to determine whether KIM-1 or NGAL are showing abnormalities in trial subjects.",
          "tokens_used": 5860
        }
      ],
      "tool_calls_made": 4,
      "total_tokens": 16662,
      "wall_time_ms": 10723.398127011023,
      "budget_violations": [
        "Cumulative result token limit exceeded: 9125 > 4096",
        "Token limit exceeded: 16662 > 16384"
      ],
      "refs_cited": [
        "clinical_signal_03_ep_004",
        "clinical_signal_03_ep_014",
        "clinical_signal_03_ep_005",
        "clinical_signal_03_ep_011",
        "clinical_signal_03_ep_003",
        "clinical_signal_03_ep_002",
        "clinical_signal_03_ep_001"
      ]
    },
    "retrieved_ref_ids": [
      "clinical_signal_03_ep_004",
      "clinical_signal_03_ep_014",
      "clinical_signal_03_ep_005",
      "clinical_signal_03_ep_011",
      "clinical_signal_03_ep_003",
      "clinical_signal_03_ep_002",
      "clinical_signal_03_ep_001"
    ],
    "valid_ref_ids": [
      "clinical_signal_03_ep_004",
      "clinical_signal_03_ep_014",
      "clinical_signal_03_ep_005",
      "clinical_signal_03_ep_011",
      "clinical_signal_03_ep_003",
      "clinical_signal_03_ep_002",
      "clinical_signal_03_ep_001"
    ]
  },
  {
    "question": {
      "question_id": "cs03_q24_evidence",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 15,
      "question_type": "evidence_sufficiency",
      "prompt": "Is there sufficient evidence at this point to convene a DSMB safety review?",
      "ground_truth": {
        "canonical_answer": "Borderline. The ALT trend in the statin subgroup is concerning but individual values are still below protocol action thresholds. A few more weeks of data showing continued escalation would strengthen the case for DSMB review.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_010",
          "clinical_signal_03_ep_013"
        ],
        "key_facts": [
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases",
          "multi-site signal distribution rules out site-specific confounders as causal explanation",
          "the hepatic enzyme pattern is consistent with a drug-drug interaction mediated through shared hepatic metabolism pathways, not direct hepatotoxicity",
          "Site 07 lab equipment issue is not the cause of ALT elevations",
          "the ALT elevation pattern correlates with statin co-administration timing, not with immune activation or antibody response patterns",
          "musculoskeletal safety endpoints track within expected ranges, confirming the safety signal is organ-specific to the liver",
          "ALT elevations appeared progressively over multiple weeks of statin co-administration with onset timing correlating with cumulative exposure duration rather than a single acute event",
          "the adverse signal is hepatic (ALT/AST elevation), not renal \u2014 kidney function markers remain stable while liver enzymes diverge"
        ]
      }
    },
    "answer": {
      "question_id": "cs03_q24_evidence",
      "answer_text": "Based on the information retrieved from the memory system, there is no evidence of safety concerns, adverse events, or significant protocol deviations that would trigger a DSMB safety review. The available documents primarily contain enrollment data and routine operational summaries [clinical_signal_03_ep_008], [clinical_signal_03_ep_004], [clinical_signal_03_ep_012], with no mention of serious adverse events or safety signals.\n\nWhile there are mentions of protocol deviations in some episodes, such as \"Dose modification without documented PI approval\" (moderate severity) [clinical_signal_03_ep_009] and \"IP temperature excursion during shipment\" (moderate severity) [clinical_signal_03_ep_013], these do not appear to represent patterns of safety concerns that would necessitate a DSMB review.\n\nWithout evidence of significant safety issues, patterns of adverse events, or critical protocol violations affecting participant safety, there is insufficient evidence at this point to convene a DSMB safety review.",
      "turns": [
        {
          "role": "assistant",
          "content": "I need to determine if there is sufficient evidence to convene a DSMB safety review. Let me first check the memory system capabilities to understand what information is available.",
          "tool_calls": [
            {
              "id": "call_d9da9caa106040c19e2acafd",
              "name": "memory_capabilities",
              "arguments": {}
            }
          ],
          "tokens_used": 782
        },
        {
          "role": "assistant",
          "content": "Now I'll search for information related to DSMB safety reviews and any evidence that might trigger such a review. I'll use a keyword search to find relevant documents.",
          "tool_calls": [
            {
              "id": "call_ef6f4c10cdc34d8ba58c0e0f",
              "name": "memory_search",
              "arguments": {
                "query": "DSMB safety review evidence",
                "limit": 7
              }
            }
          ],
          "tokens_used": 1113
        },
        {
          "role": "assistant",
          "content": "I need to search for more specific information about DSMB safety review criteria and any safety signals that might trigger such a review. The initial search didn't return any documents specifically about safety concerns or DSMB review triggers. Let me try a more targeted search.",
          "tool_calls": [
            {
              "id": "call_0d7c08543e674ecd80b721ef",
              "name": "memory_search",
              "arguments": {
                "query": "safety signal DSMB review criteria",
                "limit": 7
              }
            }
          ],
          "tokens_used": 2677
        },
        {
          "role": "assistant",
          "content": "I still don't see any specific information about safety signals or DSMB review criteria in the search results. Let me try searching specifically for safety-related events or adverse events that might trigger a DSMB review.",
          "tool_calls": [
            {
              "id": "call_1ca0228022104bf384015d6f",
              "name": "memory_search",
              "arguments": {
                "query": "adverse events safety concerns DSMB",
                "limit": 7
              }
            }
          ],
          "tokens_used": 4836
        },
        {
          "role": "assistant",
          "content": "I notice that the search results are primarily showing enrollment data and site statistics, but not any safety information or adverse events. Let me check if there are any protocol deviations or other issues that might be relevant to safety.",
          "tool_calls": [
            {
              "id": "call_f777b5dbcc624dd3a44ff46f",
              "name": "memory_search",
              "arguments": {
                "query": "protocol deviations safety",
                "limit": 7
              }
            }
          ],
          "tokens_used": 6984
        },
        {
          "role": "assistant",
          "content": "Based on the information retrieved from the memory system, there is no evidence of safety concerns, adverse events, or significant protocol deviations that would trigger a DSMB safety review. The available documents primarily contain enrollment data and routine operational summaries [clinical_signal_03_ep_008], [clinical_signal_03_ep_004], [clinical_signal_03_ep_012], with no mention of serious adverse events or safety signals.\n\nWhile there are mentions of protocol deviations in some episodes, such as \"Dose modification without documented PI approval\" (moderate severity) [clinical_signal_03_ep_009] and \"IP temperature excursion during shipment\" (moderate severity) [clinical_signal_03_ep_013], these do not appear to represent patterns of safety concerns that would necessitate a DSMB review.\n\nWithout evidence of significant safety issues, patterns of adverse events, or critical protocol violations affecting participant safety, there is insufficient evidence at this point to convene a DSMB safety review.",
          "tokens_used": 7221
        }
      ],
      "tool_calls_made": 5,
      "total_tokens": 23613,
      "wall_time_ms": 17019.227406941354,
      "budget_violations": [
        "Token limit exceeded: 16392 > 16384",
        "Cumulative result token limit exceeded: 4877 > 4096",
        "Token limit exceeded: 23613 > 16384",
        "Turn limit exceeded: 6 >= 6"
      ],
      "refs_cited": [
        "clinical_signal_03_ep_008",
        "clinical_signal_03_ep_004",
        "clinical_signal_03_ep_012",
        "clinical_signal_03_ep_009",
        "clinical_signal_03_ep_013"
      ]
    },
    "retrieved_ref_ids": [
      "clinical_signal_03_ep_008",
      "clinical_signal_03_ep_004",
      "clinical_signal_03_ep_012",
      "clinical_signal_03_ep_009",
      "clinical_signal_03_ep_013"
    ],
    "valid_ref_ids": [
      "clinical_signal_03_ep_008",
      "clinical_signal_03_ep_004",
      "clinical_signal_03_ep_012",
      "clinical_signal_03_ep_009",
      "clinical_signal_03_ep_013"
    ]
  }
]